Personalis (NASDAQ:PSNL) Releases Earnings Results, Misses Estimates By $0.06 EPS

Key Points

• Personalis reported a quarterly loss of $0.32 per share, missing analyst estimates by $0.06, while revenue of $25.6 million exceeded forecasts of $21.54 million.
• The stock rose 0.3% to $15.79 during Wednesday trading, despite the earnings miss.
• Analyst sentiment is mostly neutral: seven analysts rate PSNL Hold, three Buy and one Sell, with a consensus price target of $14.54.

Personalis (NASDAQ:PSNL - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06), FiscalAI reports. The business had revenue of $25.60 million during the quarter, compared to analyst estimates of $21.54 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%.

Personalis Stock Up 0.3%

NASDAQ PSNL traded up $0.04 during trading hours on Wednesday, hitting $15.79. The company had a trading volume of 2,217,743 shares, compared to its average volume of 2,610,416. Personalis has a fifty-two week low of $4.95 and a fifty-two week high of $18.89. The firm has a market cap of $1.65 billion, a P/E ratio of -14.49 and a beta of 2.40. The business has a fifty day simple moving average of $16.26 and a 200-day simple moving average of $11.39.

Analysts Set New Price Targets

PSNL has been the topic of a number of research reports. Lake Street Capital lowered Personalis from a "buy" rating to a "hold" rating and set a $16.25 price target on the stock. in a report on Monday, July 20th. Craig Hallum lowered shares of Personalis from a "buy" rating to a "hold" rating and set a $16.25 price objective on the stock. in a research report on Monday, August 24th. Morgan Stanley boosted their price objective on shares of Personalis from $9.00 to $13.00 and gave the company an "equal weight" rating in a research report on Thursday, July 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Personalis in a research note on Thursday, October 15th. Finally, TD Cowen reiterated a "buy" rating on shares of Personalis in a report on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $14.54.

Insiders Place Their Bets

In other Personalis news, SVP Stephen Moore sold 2,068 shares of the company's stock in a transaction on Friday, September 18th. The stock was sold at an average price of $16.22, for a total value of $33,542.96. Following the transaction, the senior vice president owned 90,257 shares of the company's stock, valued at approximately $1,463,968.54. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Richard Chen sold 3,998 shares of the firm's stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $16.22, for a total transaction of $64,847.56. Following the transaction, the chief marketing officer directly owned 169,882 shares of the company's stock, valued at $2,755,486.04. This represents a 2.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 16,456 shares of company stock valued at $266,916 over the last three months. 4.20% of the stock is currently owned by company insiders.

Personalis Company Profile

Personalis, Inc is a genomics company focused on applying advanced sequencing and bioinformatics to cancer research and precision medicine. The company develops tests and data platforms designed to help researchers and clinicians characterize tumors, monitor disease, and support the development of targeted therapies.

Its product portfolio includes the NeXT Platform, which analyzes tumor and normal DNA and RNA to provide a detailed view of cancer biology, as well as products such as NeXT Dx, NeXT Liquid Biopsy, and NeXT Personal.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.